Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs

Journal of Clinical Oncology

Volumn 33, Issue 1, 2015, Pages 100-106

  Tibau, Ariadna ^a   Bedard, Philippe L ^c   Srikanthan, Amirrtha ^c   Ethier, Josee Lyne ^c   Vera Badillo, Francisco E ^c   Templeton, Arnoud J ^d   Ocaña, Alberto ^b   Seruga, Bostjan ^e   Barnadas, Agustí ^a   Amir, Eitan ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c UNIVERSITY OF TORONTO   (Canada)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AUTHOR FINANCIAL CONFLICTS OF INTEREST; CONFLICT OF INTEREST; CONSENSUS; CONSENSUS STATEMENT; DRUG INDUSTRY; DRUG MARKETING; FINANCE; FUNDING; HUMAN; MEDLINE; PRACTICE GUIDELINE; PREVALENCE; SELF DISCLOSURE; SELF REPORT; SOLID TUMOR; SYSTEMIC THERAPY; ECONOMICS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; NEOPLASMS; PROCEDURES; PUBLICATION; PUBLISHING; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; FINANCIAL SUPPORT; HUMANS; MEDLINE; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PUBLICATIONS; PUBLISHING; RESEARCH SUPPORT AS TOPIC;

EID: 84920581345     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.8898     Document Type: Article

References (51)

1. Ransohoff DF, Pignone M, Sox HC: How to decide whether a clinical practice guideline is trustworthy. JAMA 309:139-140, 2013
2. Graham R, Mancher M, Wolman D.M., et al: (eds): Institute of Medicine: Clinical Practice Guidelines We Can Trust. Washington, DC, National Academic Press, 2011
3. Winn RJ: Oncology practice guidelines: Do they work? J Natl Compr Canc Netw 2:276-282, 2004
4. Woolf SH, Grol R, Hutchinson A., et al: Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. BMJ 318:527-530, 1999
5. Thompson DF: Understanding financial conflicts of interest. N Engl J Med 329:573-576, 1993
6. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454-465, 2003
7. Lesko R, Scott S, Stossel TP: Bias in high-tier medical journals concerning physician-academic relationships with industry. Nat Biotechnol 30:320-322, 2012
8. Drug-company influence on medical education in USA. Lancet 356:781, 2000
9. Liesegang TJ: Physicians and the pharmaceutical industry: Is a gift ever just a gift? Wazana A: JAMA 2000; 283:373-380.
10. Am J Ophthalmol 130: 261, 2000
11. Moy B, Bradbury AR, Helft P.R., et al: Correlation between financial relationships with commercial interests and research prominence at an oncology meeting. J Clin Oncol 31:2678-2684, 2013
12. Hampson LA, Joffe S, Fowler R., et al: Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. J Clin Oncol 25:3609-3614, 2007
13. Johnston KL, Go RS: Financial conflicts of interest among ASCO annual meeting abstract authors, speakers, and planners. J Natl Cancer Inst 99:1415-1416, 2007
14. Lockhart AC, Brose MS, Kim E.S., et al: Physician and stakeholder perceptions of conflict of interest policies in oncology. J Clin Oncol 31:1677-1682, 2013
15. Peppercorn J, Blood E, Winer E., et al: Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109:1239-1246, 2007
16. Riechelmann RP, Wang L, O'Carroll A, et al: Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology. J Clin Oncol 25:4642-4647, 2007
17. Flanagin A, Carey LA, Fontanarosa P.B., et al: Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280:222-224, 1998
18. Wislar JS, Flanagin A, Fontanarosa P.B., et al: Honorary and ghost authorship in high impact biomedical journals: A cross sectional survey. BMJ 343:d6128, 2011
19. Gotzsche PC, Hróbjartsson A, Johansen H.K., et al: Ghost authorship in industry-initiated randomised trials. PLoS Med 4:e19, 2007
20. Reames BN, Krell RW, Ponto S.N., et al: Critical evaluation of oncology clinical practice guidelines. J Clin Oncol 31:2563-2568, 2013
21. Grilli R, Magrini N, Penna A., et al: Practice guidelines developed by specialty societies: The need for a critical appraisal. Lancet 355:103-106, 2000
22. American Society of Clinical Oncology: Policy for relationships with companies. J Clin Oncol 31: 2043-2046, 2013
23. Saint S, Christakis DA, Saha S, et al: Journal reading habits of internists. J Gen Intern Med 15: 881-884, 2000
24. Barry HC, Ebell MH, Shaughnessy A.F., et al: Family physicians' use of medical abstracts to guide decision making: Style or substance? J Am Board Fam Pract 14:437-442, 2001
25. Berwanger O, Ribeiro RA, Finkelsztejn A, et al: The quality of reporting of trial abstracts is suboptimal: Survey of major general medical journals. J Clin Epidemiol 62:387-392, 2009
26. Djulbegovic B, Lacevic M, Cantor A., et al: The uncertainty principle and industry-sponsored research. Lancet 356:635-638, 2000
27. Stelfox HT, Chua G, O'Rourke K, et al: Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338:101-106, 1998
28. Lundh A, Sismondo S, Lexchin J., et al: Industry sponsorship and research outcome. Cochrane Database Syst Rev 12:MR000033, 2012
29. Als-Nielsen B., Chen W, Gluud C., et al: Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? JAMA 290:921-928, 2003
30. Friedberg M, Saffran B, Stinson T.J., et al: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282: 1453-1457, 1999
31. Mendelson TB, Meltzer M, Campbell E.G., et al: Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med 171:577-584, 2011
32. Norris SL, Holmer HK, Ogden L.A., et al: Conflicts of interest among authors of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PLoS One 8:e75284, 2013
33. Holloway RG, Mooney CJ, Getchius T.S., et al: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelines. Neurology 71:57-63, 2008
34. Lo B: Serving two masters: Conflicts of interest in academic medicine. N Engl J Med 362:669-671, 2010
35. Jagsi R, Sheets N, Jankovic A., et al: Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer 115:2783-2791, 2009
36. Campbell EG, Weissman JS, Vogeli C, et al: Financial relationships between institutional review board members and industry. N Engl J Med 355: 2321-2329, 2006
37. Choudhry NK, Stelfox HT, Detsky AS: Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287: 612-617, 2002
38. Jones DJ, Barkun AN, Lu Y, et al: Conflicts of interest ethics: Silencing expertise in the development of international clinical practice guidelines. Ann Intern Med 156:809-816, W-283, 2012
39. Irwin RS: The role of conflict of interest in reporting of scientific information. Chest 136:253-259, 2009
40. American Society of Clinical Oncology: The changing landscape of conflict of interest supports further study of American Society of Clinical Oncology authorship restrictions for research studies. J Clin Oncol 32:867-868, 2014
41. National Institute for Health and Clinical Excellence: A Code of Practice for Declaring and Dealing With Conflicts of Interest. London, United Kingdom, National Institute for Health and Clinical Excellence, 2008
42. Physician Payments Sunshine Act. http://www.ama-assn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financial-transparency-reports.page
43. American College of Cardiology Foundation, American Heart Association: Methodologies and policies from ACCF/AHA Taskforce on Practice Guidelines. http://my.americanheart.org/professional/StatementsGuidelines/PoliciesDevelopment/Development/Methodologies-and-Policies-from-the-ACCAHA-Task-Force-on-Practice-Guidelines-UCM-320470-Article.jsp
44. Barbour V: How ghost-writing threatens the credibility of medical knowledge and medical journals. Haematologica 95:1-2, 2010
45. Woolley KL, Ely JA, Woolley M.J., et al: Declaration of medical writing assistance in international peer-reviewed publications. JAMA 296:932-934, 2006
46. Rothman DJ, McDonald WJ, Berkowitz C.D., et al: Professional medical associations and their relationships with industry: A proposal for controlling conflict of interest. JAMA 301:1367-1372, 2009
47. Okike K, Kocher MS, Wei E.X., et al: Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med 361:1466-1474, 2009
48. Blumenthal D: Doctors and drug companies. N Engl J Med 351:1885-1890, 2004
49. Loewenstein G, Sah S, Cain DM: The unintended consequences of conflict of interest disclosure. JAMA 307:669-670, 2012
50. Saver RS: Is it really all about the money? Reconsidering non-financial interests in medical research. J Law Med Ethics 40:467-481, 2012
51. Council of Medical Specialty Societies: Code for interactions with companies. http://www.cmss.org/codeforinteractions.aspx